UNSPSC 51422423: Flunisolide acetate

This classification denotes a therapeutic glucocorticoid C26H33FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N225H64CIH, chemically known as pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6.alpha.,11.beta.,16.alpha.)-, but more generally known as flunisolide acetate, which bears US NIH Compound Identifier 23724908. European Medicines Agency schedules Flunisolide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13898MIG.

Most nations, for tariff and trade purposes, schedule flunisolide acetate under HS 29372200 and SITC 54153. As of Q4 2014, FLUNISOLIDE ACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@H]4[C@H]3C[C@@H](C5=CC(=O)C=C[C@]45C)F)O)C)OC(O2)(C)C.

UNSPSC 51422423 Flunisolide acetate is a Commodity code that nominally refers to a specific inhaled corticosteroid pharmaceutical product, yet the recent state and local opportunities tagged under this code show no alignment with flunisolide procurement. Instead, the opportunities solicited relate to naloxone (an opioid antagonist) and direct-to-manufacturer prescription program administration—products and services substantially outside the scope of a single corticosteroid formulation. The mismatch suggests either tagging inconsistency in the source data or that this code is used as a placeholder for broader pharmaceutical purchasing activities within certain procurement systems. State and local health departments and human services agencies appear to be the issuing bodies, but the limited recent activity and the disconnect between the code's nominal scope and actual solicitations make this code an unreliable signal for flunisolide-specific demand.

The two recent opportunities show geographic spread across Florida and Texas. Seminole County, Florida posted IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the posted date and due date are inconsistent in the source), and the Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription programs without a formal response timeline. No active procurement opportunities for flunisolide acetate specifically have been identified in the recent state and local contract activity under this code.